Treatment of cognitive impairment of hunter syndrome by intrathecal delivery of iduronate-2-sulfatase
US11357832B2 · kind B2 · utility
0Cited by
6References
17Claims
0Family size
Assignee
Inventors
Key dates
| Filing date | Jan 15, 2020 |
| Grant date | Jun 14, 2022 |
| Priority date | — |
| Expiry date | Jan 15, 2040 |
Classification
- Technology area (CPC C)Chemistry; Metallurgy
- CPC primaryC12Y301/06013
- WIPO fieldPharmaceuticals
- WIPO sectorChemistry
Abstract
The present invention, provides a method of treating cognitive impairment of Hunter syndrome. Among other things, the present invention provides a method comprising a step of administering intrathecally to a subject in need of treatment a recombinant iduronate-2-sulfatase (I2S) enzyme at a therapeutically effective dose and an administration interval for a treatment period sufficient to improve, stabilize or reduce declining of one or more cognitive, adaptive, motor, and/or executive functions relative to a control.
Source: USPTO / EPO open patent data. Objective bibliographic and citation counts.